Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial

Authors: Ruo-Xi Hong, Fei Xu, Wen Xia, Yue-E Teng, Qu-Chang Ouyang, Qiu-Fan Zheng, Zhong-Yu Yuan, Dong-Shao Chen, Kui-Kui Jiang, Ying Lin, Zhen Dai, Xin-Lan Liu, Qian-Jun Chen, Xin-Hong Wu, Yan-Xia Shi, Jia-Jia Huang, Xin An, Cong Xue, Xi-Wen Bi, Mei-Ting Chen, Hui Li, He-Rui Yao, Guo-Rong Zou, Heng Huang, Jing-Min Zhang, Shu-Sen Wang

Published: 2025-01-02

DOI: 10.1200/jco.24.00938

Source: Full article

---

Abstract

PURPOSE